spacer
home > ebr > winter 2002 > patent protection for genes and other parts of the human body under ec law
PUBLICATIONS
European Biopharmaceutical Review

Patent Protection for Genes and Other Parts of the Human Body under EC Law

After a decade of heated controversies, in 1998 the Council of the European Union and the European Parliament finally adopted the European Community's Directive 98/44/EC on the Legal Protection of Biotechnological Inventions (1). The EC Biotechnology Directive was hailed as a breakthrough in favour of the necessary incentives for research and development, especially in the area of diagnostic and therapeutic tools as well as new pharmaceuticals (2). However, recent controversies have rekindled the legal battle over patents on genes and DNA sequences. In particular, the patent on the BRCA gene (3) (related to breast cancer) raises highly plausible concerns about exclusive rights over the gene's diagnostic functions and the use of all proteins coded for by the patented DNA sequence. Within the scientific community, the call for a cautious approach to patents on DNA sequences has gathered considerable force (4).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Professor Matthias Herdegen, Director of the Institute of International Law and the Institute for Public Law, University of Bonn Professor Matthias Herdegen is Director of the Institute of International Law and the Institute for Public Law at the University of Bonn.
He is the editor and author of a loose-leaf collection on international biotechnology law, which includes the legislation of the EU, European countries, the US, Japan, China and other countries and international treaties, as well as commentaries on these legal instruments.

spacer
Professor Matthias Herdegen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement